ArticleFrontiers in microbiology2020
Engineered Lysins With Customized Lytic Activities Against Enterococci and Staphylococci.
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Integrated computational and experimental benchmarking of Bacillus phage endolysins reveals the relationship between peptidoglycan-fragment recognition descriptors and antibacterial performance.Scientific reports · 2026Article
- DepoCatalog: mapping diversity of 129 recombinantly produced Klebsiella phage depolymerases.Nature communications · 2026Article
- Antibacterial Activity of Bacteriophage Lytic Enzyme Ply900.Veterinary sciences · 2026Article
- A novel broad-spectrum phage lysin CP02 for biocontrol ofCurrent research in food science · 2026Article
- Next-generation antimicrobials: A review of phage lysins as precision weapons against drug-resistant pathogens.Virulence · 2025Review
- A Novel Enterococcus Phage Endolysin Lys22 with a Wide Host Range Against Mixed Biofilm ofPathogens (Basel, Switzerland) · 2025Article
- Characterization of Two Novel Endolysins from Bacteriophage PEF1 and Evaluation of Their Combined Effects on the Control ofAntibiotics (Basel, Switzerland) · 2024Article
- Article
- Gene and domain shuffling in lytic cassettes of3 Biotech · 2023Article
- Development of a Magnetic Bead-Based Method for Specific Detection ofJournal of microbiology and biotechnology · 2023Article
- Bacteriolytic Potential ofViruses · 2023Article
- Construction and Activity Testing of a Modular Fusion Peptide againstAntibiotics (Basel, Switzerland) · 2023Article
- Megaprimer-Based PCR to Synthesize Fusion Genes for Cloning.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Vancomycin Resistance inMicroorganisms · 2022Review
- inPhocus: Current State and Challenges of Phage Research in Singapore.PHAGE (New Rochelle, N.Y.) · 2022Article
- Novel Phage Lysin Abp013 againstAntibiotics (Basel, Switzerland) · 2022Article
- Phage Revolution Against Multidrug-Resistant Clinical Pathogens in Southeast Asia.Frontiers in microbiology · 2022Review
- inPhocus: The Diverse Landscape of Phage Studies in the Association of Southeast Asian Nations Region.PHAGE (New Rochelle, N.Y.) · 2021Article
- Article
- Phage lysins for intestinal microbiome modulation: current challenges and enabling techniques.Gut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of multidrug-resistant bacteria has made minor bacterial infections incurable with many existing antibiotics. Lysins are phage-encoded peptidoglycan hydrolases that have demonstrated therapeutic potential as a novel class of antimicrobials. The modular architecture of lysins enables the functional domains - catalytic domain (CD) and cell wall binding domain (CBD) - to be shuffled to create novel lysins. The CD is classically thought to be only involved in peptidoglycan hydrolysis whereas the CBD dictates the lytic spectrum of a lysin. While there are many studies that extended the lytic spectrum of a lysin by domain swapping, few have managed to introduce species specificity in a chimeric lysin. In this work, we constructed two chimeric lysins by swapping the CBDs of two parent lysins with different lytic spectra against enterococci and staphylococci. We showed that these chimeric lysins exhibited customized lytic spectra distinct from the parent lysins. Notably, the chimeric lysin P10N-V12C, which comprises a narrow-spectrum CD fused with a broad-spectrum CBD, displayed species specificity not lysing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.